Tolerance Profile of the Proliferation Signal Inhibitors Everolimus and Sirolimus in Heart Transplantation
- 1 November 2008
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (9) , 3034-3036
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- mTOR Inhibitors and Their Secondary Effects in Cardiac Trasplant Recipients: A Descriptive StudyTransplantation Proceedings, 2007
- Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III StudyTransplantation, 2005
- Clinical Experience with Everolimus (Certican): Optimizing Dose and TolerabilityTransplantation, 2005
- Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant PatientsAmerican Journal of Transplantation, 2005
- Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1Transplantation, 2005
- Drug Therapy in the Heart Transplant RecipientCirculation, 2004
- Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant RecipientsTransplantation, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003